Jun 2, 2026
NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine
Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.
1 source
00